JSPR (Jasper Therapeutics, Inc.) Stock Financials & Earnings

JSPRJasper Therapeutics, Inc.

Mkt Cap$23M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$91M

EPS (TTM)-$5.90

Free Cash Flow (TTM)-$77M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

▶Q3 2025

Next: Q4 2025 · Mar 12

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commerc...

CEO Jeetinder Singh MahalIPO Jan 10, 2020jaspertherapeutics.com

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$0	$0	-$14M
Q1 23	$0	$0	-$14M
Q2 23	$0	$0	-$18M
Q3 23	$0	$0	-$19M
Q4 23	$0	$0	-$18M
Q1 24	$0	-$288K	-$15M
Q2 24	$0	$0	-$16M
Q3 24	$0	$0	-$20M
Q4 24	$0	$0	-$25M
Q1 25	$0	$0	-$22M
Q2 25	$0	$0	-$27M
Q3 25	$0	$0	-$19M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 22	-$13M	-$13M
Q1 23	-$10M	-$10M
Q2 23	-$13M	-$13M
Q3 23	-$12M	-$12M
Q4 23	-$16M	-$17M
Q1 24	-$16M	-$16M
Q2 24	-$12M	-$12M
Q3 24	-$14M	-$14M
Q4 24	-$21M	-$21M
Q1 25	-$23M	-$23M
Q2 25	-$15M	-$15M
Q3 25	-$17M	-$17M

Capital Expenditures

CapEx

Quarter	CapEx
Q4 22	$82K
Q1 23	$26K
Q2 23	$11K
Q3 23	$0
Q4 23	$230K
Q1 24	$25K
Q2 24	$157K
Q3 24	$274K
Q4 24	$96K
Q1 25	$0
Q2 25	$7K
Q3 25	$0

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	—	+13.8%
Q1 23	—	+9.1%
Q2 23	—	+49.0%
Q3 23	—	+52.4%
Q4 23	—	+28.9%
Q1 24	—	+8.1%
Q2 24	—	-10.3%
Q3 24	—	+2.7%
Q4 24	—	+42.7%
Q1 25	—	+44.7%
Q2 25	—	+69.3%
Q3 25	—	-3.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 22	$0	—
Q1 23	$1M	—
Q2 23	$0	—
Q3 23	$1M	—
Q4 23	$1M	—
Q1 24	$1M	—
Q2 24	$1M	—
Q3 24	$0	—
Q4 24	$2M	—
Q1 25	$2M	—
Q2 25	$2M	—
Q3 25	$1M	—

OpEx Breakdown

Quarter	R&D	G&A
Q4 22	$9M	$4M
Q1 23	$10M	$4M
Q2 23	$13M	$5M
Q3 23	$15M	$5M
Q4 23	$14M	$4M
Q1 24	$10M	$5M
Q2 24	$11M	$5M
Q3 24	$14M	$5M
Q4 24	$20M	$6M
Q1 25	$16M	$6M
Q2 25	$21M	$6M
Q3 25	$14M	$5M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$38M	$0	$38M
Q1 23	$129M	$0	$129M
Q2 23	$116M	$0	$116M
Q3 23	$104M	$0	$104M
Q4 23	$87M	$0	$87M
Q1 24	$118M	$0	$118M
Q2 24	$107M	$0	$107M
Q3 24	$93M	$0	$93M
Q4 24	$72M	$0	$72M
Q1 25	$49M	$0	$49M
Q2 25	$40M	$0	$40M
Q3 25	$51M	$0	$51M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q4 22	4M	+0.2%
Q1 23	9M	+139.8%
Q2 23	11M	+24.3%
Q3 23	11M	+0.5%
Q4 23	11M	+0.7%
Q1 24	13M	+20.7%
Q2 24	15M	+12.4%
Q3 24	15M	+0.1%
Q4 24	15M	+0.1%
Q1 25	15M	+0.1%
Q2 25	15M	+2.1%
Q3 25	17M	+8.5%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 19	$0	3
FY 20	$0	3
FY 21	$0	25
FY 22	$0	35
FY 23	$0	45
FY 24	$0	64